Get the Stockscreener App
1.55
3.13%
-0.05
After Hours:
1.53
-0.02
-1.29%
Aldeyra Therapeutics Inc stock is traded at $1.55, with a volume of 1.47M.
It is down -3.13% in the last 24 hours and down -17.11% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.60
Open:
$1.58
24h Volume:
1.47M
Relative Volume:
0.51
Market Cap:
$93.28M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.7492
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-13.89%
1M Performance:
-17.11%
6M Performance:
-70.42%
1Y Performance:
-41.51%
1-Day Range:
$1.5101
$1.59
1-Week Range:
$1.5101
$1.835
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.55 | 93.28M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to ... - Bluefield Daily Telegraph
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Coty Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – COTY - GlobeNewswire Inc.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Aldeyra - GlobeNewswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ALDX Shareholder Alert: May 29, 2026 Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. ... - Bluefield Daily Telegraph
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: SueWallSt - Barchart.com
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX (Aldeyra Therapeutics Inc.) reports narrower Q4 2025 loss than forecast, topping consensus EPS estimates by 60 percent.Decline Phase - Xã Thanh Hà
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have - The National Law Review
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role - Business Wire
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Daily Tribune News
2026-04-22 | ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ALDX | Press Release - Stockhouse
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Aldeyra Therapeutics Announces Upcoming Board Member Departure - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - FinancialContent
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - ChartMill
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - Barchart.com
Aldeyra Therapeutics director Martin J. Joyce to step down after annual meeting By Investing.com - Investing.com South Africa
Aldeyra Therapeutics director Martin J. Joyce to step down after annual meeting - Investing.com
Martin J. Joyce to Not Seek Re-election to Aldeyra Board - TradingView
Aldeyra Therapeutics (NASDAQ: ALDX) director to exit after 2026 vote - Stock Titan
ADLX Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
Aldeyra (ALDX) Stock: What Investors Should Know (-1.67%) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, THE FIRST FILING FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - Sahm
Aldeyra Therapeutics (NASDAQ:ALDX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra The - GuruFocus
ALDX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky - TipRanks
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. - GlobeNewswire
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Down 14.6% in March - MarketBeat
Aldeyra Therapeutics (ALDX) price target decreased by 22.41% to 7.65 - MSN
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmALDX - ACCESS Newswire
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
Robbins LLP Investigating Aldeyra Therapeutics for Misleading Investors - National Today
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.01%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):